• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    5/22/24 4:31:33 PM ET
    $CGTX
    $CING
    $CLSD
    $CYTK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CGTX alert in real time by email

    Gainers

    • Sharps Technology (NASDAQ:STSS) stock increased by 56.5% to $0.4 during Wednesday's after-market session. The market value of their outstanding shares is at $6.3 million.
    • Geovax Labs (NASDAQ:GOVX) shares moved upwards by 21.71% to $2.27. The market value of their outstanding shares is at $5.2 million.
    • NexImmune (NASDAQ:NEXI) stock increased by 9.52% to $3.45. The company's market cap stands at $4.7 million. As per the news, the Q1 earnings report came out 2 days ago.
    • Cognition Therapeutics (NASDAQ:CGTX) stock rose 8.04% to $2.83. The market value of their outstanding shares is at $113.3 million.
    • Clearside Biomedical (NASDAQ:CLSD) shares rose 7.39% to $1.45. The market value of their outstanding shares is at $108.3 million.
    • Unicycive Therapeutics (NASDAQ:UNCY) stock moved upwards by 6.46% to $1.07. The market value of their outstanding shares is at $40.2 million.

    Losers

    • TransCode Therapeutics (NASDAQ:RNAZ) shares decreased by 13.2% to $1.25 during Wednesday's after-market session. The market value of their outstanding shares is at $8.2 million.
    • Cytokinetics (NASDAQ:CYTK) stock declined by 11.54% to $52.4. The company's market cap stands at $5.4 billion.
    • NovaBay Pharmaceuticals (AMEX:NBY) stock fell 7.3% to $0.13. The market value of their outstanding shares is at $4.9 million.
    • Qilian Intl Hldg Gr (NASDAQ:QLI) shares declined by 6.44% to $0.58. The market value of their outstanding shares is at $20.7 million.
    • SenesTech (NASDAQ:SNES) stock declined by 6.24% to $0.75. The market value of their outstanding shares is at $3.8 million.
    • Cingulate (NASDAQ:CING) shares fell 6.23% to $0.76. The company's market cap stands at $4.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $CGTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CGTX
    $CING
    $CLSD
    $CYTK

    CompanyDatePrice TargetRatingAnalyst
    GeoVax Labs Inc.
    $GOVX
    2/19/2026Buy → Hold
    D. Boral Capital
    Cytokinetics Incorporated
    $CYTK
    1/28/2026$87.00Overweight
    Barclays
    Cytokinetics Incorporated
    $CYTK
    12/18/2025$95.00Neutral → Buy
    Goldman
    Cytokinetics Incorporated
    $CYTK
    7/30/2025Mkt Perform
    Raymond James
    Clearside Biomedical Inc.
    $CLSD
    7/18/2025$2.00Buy → Hold
    Stifel
    Clearside Biomedical Inc.
    $CLSD
    7/18/2025Buy → Neutral
    Chardan Capital Markets
    Clearside Biomedical Inc.
    $CLSD
    7/18/2025Buy → Neutral
    H.C. Wainwright
    Cytokinetics Incorporated
    $CYTK
    4/24/2025$55.00Overweight
    Barclays
    More analyst ratings

    $CGTX
    $CING
    $CLSD
    $CYTK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GeoVax Labs downgraded by D. Boral Capital

    D. Boral Capital downgraded GeoVax Labs from Buy to Hold

    2/19/26 8:44:06 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays resumed coverage on Cytokinetics with a new price target

    Barclays resumed coverage of Cytokinetics with a rating of Overweight and set a new price target of $87.00

    1/28/26 7:16:37 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics upgraded by Goldman with a new price target

    Goldman upgraded Cytokinetics from Neutral to Buy and set a new price target of $95.00

    12/18/25 8:41:18 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CGTX
    $CING
    $CLSD
    $CYTK
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XIPERE issued to CLEARSIDE BIOMEDICAL, INC

    Submission status for CLEARSIDE BIOMEDICAL, INC's drug XIPERE (ORIG-1) with active ingredient TRIAMCINOLONE ACETONIDE has changed to 'Approval' on 10/22/2021. Application Category: NDA, Application Number: 211950, Application Classification: Type 3 - New Dosage Form

    10/25/21 2:22:37 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SUSVIMO issued to CLEARSIDE BIOMEDICAL, INC

    Submission status for CLEARSIDE BIOMEDICAL, INC's drug SUSVIMO (ORIG-1) with active ingredient RANIBIZUMAB has changed to 'Approval' on 10/22/2021. Application Category: NDA, Application Number: 211950, Application Classification: Type 3 - New Dosage Form

    10/25/21 2:07:19 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CGTX
    $CING
    $CLSD
    $CYTK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Kazley Michael John

    4 - Stablecoin Development Corp (0001389545) (Issuer)

    4/2/26 9:44:59 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Sit Swan

    4 - Stablecoin Development Corp (0001389545) (Issuer)

    4/2/26 4:54:10 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Blum Robert I

    4 - CYTOKINETICS INC (0001061983) (Issuer)

    4/1/26 4:34:40 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CGTX
    $CING
    $CLSD
    $CYTK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $330,182 worth of shares (171,034 units at $1.93) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    3/17/26 8:10:19 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $200,635 worth of shares (85,901 units at $2.34) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/19/26 7:57:41 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $56,667 worth of shares (31,346 units at $1.81) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/13/26 5:20:17 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $CGTX
    $CING
    $CLSD
    $CYTK
    SEC Filings

    View All

    Cingulate Inc. filed SEC Form 8-K: Leadership Update

    8-K - Cingulate Inc. (0001862150) (Filer)

    4/2/26 4:05:28 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NovaBay Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - Stablecoin Development Corp (0001389545) (Filer)

    4/1/26 4:23:55 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GeoVax Labs Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - GeoVax Labs, Inc. (0000832489) (Filer)

    3/31/26 5:15:01 PM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CGTX
    $CING
    $CLSD
    $CYTK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cognition Therapeutics CEO Issues Letter to Shareholders

    Advancing Zervimesine (CT1812) towards late-stage trials for dementia with Lewy bodies (DLB) psychosis Fully funded $80 million Phase 2 START trial readout expected in the second half of 2027 PURCHASE, N.Y., March 31, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders, has published CEO Lisa Ricciardi's Letter to Shareholders. The full text of the letter follows. A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER To my fellow Shareholders, We made significant progress in 2025 towards our goal of developing transformative treatments for neurodegenerative diseases. As discussed on our

    3/31/26 4:30:00 PM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

    Oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission under review by U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026Commercial readiness activities ongoing in anticipation of potential commercial launch of OLC in 3Q26As of March 30, 2026 unaudited cash, cash equivalents, and marketable securities totaled $54.9 million, with expected runway into 2027 LOS ALTOS, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the full year ended D

    3/30/26 7:05:00 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

    -Advancing zervimesine clinical development in DLB psychosis – - Meeting with FDA Division of Psychiatry expected by mid-2026 -- Management conference call at 8:30 a.m. ET today - PURCHASE, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), today reported financial results for the fourth quarter and full year ended December 31, 2025. Management will host a live webcast conference call at 8:30 a.m. ET to review these financial results and provide an update on clinical development plans for zervimesine (CT1812) in dementia with Lewy

    3/26/26 7:30:00 AM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGTX
    $CING
    $CLSD
    $CYTK
    Leadership Updates

    Live Leadership Updates

    View All

    SenesTech Announces CEO Transition Plan

    Board To Initiate Search For New Leadership As Current CEO Plans Retirement Dr. Jamie Bechtel Named Interim Executive Chair To Further Support Transition PHOENIX, Jan. 28, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a pioneer in fertility control solutions for managing rodent populations, today announced that Joel Fruendt, President and Chief Executive Officer, has informed the Board of Directors of his intent to retire. The Board will commence a formal search for a successor. Mr. Fruendt will continue to serve as President and CEO until the search is completed or until June 30, 2026, whichever occurs first.

    1/28/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)

    "On Track with HCM" Features Practical Insights for Managing Everyday Life with the Disease, Inspired by the Experience with HCM of McLaughlin-Levrone's Father, Willie McLaughlin SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the launch of "On Track with HCM," demonstrating the company's long-standing commitment to the HCM community. The campaign features four-time Olympic gold medalist Sydney McLaughlin-Levrone, and her father, three-time all-American track star, Willie McLaughlin, who suffered from the non-obstructive form of hypertrophic cardiomyopathy (HCM) for more than two decades before receiving a heart trans

    1/27/26 8:00:00 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

    BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee.  Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation.

    12/22/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CGTX
    $CING
    $CLSD
    $CYTK
    Financials

    Live finance-specific insights

    View All

    Cognition Therapeutics CEO Issues Letter to Shareholders

    Advancing Zervimesine (CT1812) towards late-stage trials for dementia with Lewy bodies (DLB) psychosis Fully funded $80 million Phase 2 START trial readout expected in the second half of 2027 PURCHASE, N.Y., March 31, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders, has published CEO Lisa Ricciardi's Letter to Shareholders. The full text of the letter follows. A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER To my fellow Shareholders, We made significant progress in 2025 towards our goal of developing transformative treatments for neurodegenerative diseases. As discussed on our

    3/31/26 4:30:00 PM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

    Oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission under review by U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026Commercial readiness activities ongoing in anticipation of potential commercial launch of OLC in 3Q26As of March 30, 2026 unaudited cash, cash equivalents, and marketable securities totaled $54.9 million, with expected runway into 2027 LOS ALTOS, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the full year ended D

    3/30/26 7:05:00 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

    -Advancing zervimesine clinical development in DLB psychosis – - Meeting with FDA Division of Psychiatry expected by mid-2026 -- Management conference call at 8:30 a.m. ET today - PURCHASE, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), today reported financial results for the fourth quarter and full year ended December 31, 2025. Management will host a live webcast conference call at 8:30 a.m. ET to review these financial results and provide an update on clinical development plans for zervimesine (CT1812) in dementia with Lewy

    3/26/26 7:30:00 AM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGTX
    $CING
    $CLSD
    $CYTK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:28:08 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by Cingulate Inc.

    SC 13G/A - Cingulate Inc. (0001862150) (Subject)

    11/14/24 7:21:05 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Unicycive Therapeutics Inc.

    SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

    11/14/24 7:13:38 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care